A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Allovir, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 776,857 shares of ALVR stock, worth $365,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
776,857
Previous 791,200 1.81%
Holding current value
$365,122
Previous $569,000 10.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.7 - $0.82 $10,040 - $11,761
-14,343 Reduced 1.81%
776,857 $629,000
Q2 2024

Aug 09, 2024

SELL
$0.72 - $0.82 $50,611 - $57,641
-70,294 Reduced 8.16%
791,200 $569,000
Q1 2024

May 13, 2024

BUY
$0.64 - $0.78 $63,698 - $77,632
99,529 Added 13.06%
861,494 $650,000
Q4 2023

Feb 13, 2024

BUY
$0.68 - $2.39 $291,205 - $1.02 Million
428,243 Added 128.32%
761,965 $518,000
Q3 2023

Nov 14, 2023

BUY
$2.15 - $3.64 $57,226 - $96,885
26,617 Added 8.67%
333,722 $718,000
Q2 2023

Aug 11, 2023

SELL
$3.17 - $5.82 $446,003 - $818,844
-140,695 Reduced 31.42%
307,105 $1.04 Million
Q1 2023

May 12, 2023

BUY
$3.94 - $7.05 $133,960 - $239,700
34,000 Added 8.22%
447,800 $1.76 Million
Q4 2022

Feb 13, 2023

BUY
$4.7 - $9.98 $579,040 - $1.23 Million
123,200 Added 42.4%
413,800 $2.12 Million
Q3 2022

Nov 14, 2022

SELL
$4.13 - $8.79 $45,847 - $97,577
-11,101 Reduced 3.68%
290,600 $2.29 Million
Q2 2022

Aug 12, 2022

BUY
$3.26 - $7.06 $810,439 - $1.76 Million
248,601 Added 468.18%
301,701 $1.18 Million
Q1 2022

May 13, 2022

BUY
$6.75 - $13.52 $358,425 - $717,912
53,100 New
53,100 $358,000
Q3 2021

Nov 12, 2021

SELL
$16.97 - $25.06 $475,159 - $701,680
-28,000 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$19.44 - $25.06 $544,320 - $701,680
28,000 New
28,000 $553,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $43.7M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.